2020年湖北省某医院救治新冠肺炎患者的抗病毒药物使用分析  

Analysis of the use for antiviral drugs in the treatment of COVID-19 patients in a Hubei hospital in 2020

作　　者：庞素秋[1] PANG Suqiu(No.910 Hospital of Joint Logistics Support Force of the PLA,Quanzhou 362000,China)

机构地区：[1]中国人民解放军联勤保障部队第910医院,福建泉州362000

出　　处：《药学实践与服务》2022年第6期583-586,共4页Journal of Pharmaceutical Practice and Service

摘　　要：目的回顾性分析湖北省某医院救治1765名新冠肺炎患者的抗病毒药物使用情况,为临床合理用药提供经验和建议。方法依据国家卫健委《新型冠状病毒肺炎诊疗方案》推荐用药,对湖北省某医院在2020年2—4月救治新冠肺炎患者期间的抗病毒用药进行分析。结果收治的1765名患者中,1114名患者使用了抗病毒药物,占63.11%;使用率排名前3位的抗病毒药物分别为阿比多尔981例(55.58%)、干扰素α-2b 340例(19.26%)和氯喹72例(4.08%),排名前3的药物占所有抗病毒药物的80.61%;在治疗方案上,单用阿比多尔的636例,占57.09%,单用干扰素α-2b的98例,占8.8%,阿比多尔联合干扰素α-2b的164例,占14.72%;干扰素α-2b、阿比多尔、氯喹均存在超过20%的超疗程用药;6例病人抗病毒用药超过3种,50例病人使用了未被诊疗方案(第八版)推荐的羟氯喹。结论该院治疗新冠肺炎患者的抗病毒治疗用药,基本上是在国家卫健委同时段不断更新的《新型冠状病毒肺炎诊疗方案》指导下合理使用。Objective To retrospectively analyze the use of antiviral drugs in 1765 patients admitted to a hospital of COVID-19 in Hubei Province,and to provide experience and suggestions for clinical rational drug use.Methods The antiviral drugs used in a hospital in Hubei Province during the treatment of COVID-19 patients from February to April 2020 were analyzed according to the"New Coronary Virus Pneumonia Diagnosis and Treatment Program"recommendated by the National Health Commission.Results Among the 1765 patients,1114(63.11%)were treated with antiviral drugs.The top three antiviral drugs were arbidol(981 cases,use rate 55.58%),IFN-α-2b(340 cases,use rate 19.26%)and chloroquine(72 cases,use rate 4.08%).Among all the antiviral regimens,636(57.09%)were treated with arbidol alone,followed by arbidol combined IFN-α-2b 164(14.72%),arbidol combined IFN-α-2b 98(8.8%),and the top three regimens accounted for 80.61%of all antiviral regimens.According to the COVID-19,IFN-α-2b,Arbidol,and chloroquine had more than 20%of the over-treatment duration,6 patients used more than 3 antiviral drugs,and 50 patients had not been recommended for hydroxychloroquine.Conclusion The antiviral drugs used for the treatment of patients with COVID-19 in this hospital are basically used rationally under the guidance of the"New Coronary Virus Pneumonia Diagnosis and Treatment Program"continuously updated by the National Health Commission at the same time..

关 键 词：新冠肺炎 抗病毒药 用药分析 药学监护 

分 类 号：R95[医药卫生—药学]